Motivated by these findings, we further explored the effect of the IRE1α–XBP1 pathway on the anti-tumor activity against MM by using the novel ‘mono’-specific inhibitor of IRE1α, KIRA8, in this study. Here, XBP1 is linked to neoplasm.